Aurdan Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$513K Buy
428
+12
+3% +$12.3K 0.13% 64
2026
Q1
$383K Buy
416
+12
+3% +$12.2K 0.11% 69
2025
Q4
$434K Hold
404
0.13% 67
2025
Q3
$308K Hold
404
0.1% 76
2025
Q2
$315K Hold
404
0.11% 77
2025
Q1
$334K Sell
404
-202
-33% -$168K 0.13% 71
2024
Q4
$468K Buy
+606
New +$502K 0.18% 60

Other funds holding LLY

Aurdan Capital Management's LLY Position: Q2 2026 in Review

Aurdan Capital Management increased its Eli Lilly (LLY) stake by 2.9% in Q2 2026, buying an estimated $12.3K and bringing the position to 428 shares worth $513K. The position accounts for 0.13% of the portfolio, ranked #64.

Aurdan Capital Management first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 1,570 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Aurdan Capital Management held 428 shares of Eli Lilly worth $513K as of Q2 2026.
  • Aurdan Capital Management bought 12 Eli Lilly shares in Q2 2026, an estimated $12.3K.
  • Eli Lilly made up 0.13% of Aurdan Capital Management's portfolio in Q2 2026, its #64 holding.
  • Aurdan Capital Management first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 1,570 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Aurdan Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.